Plano, Texas Mar 31, 2021 (Issuewire.com) - Shraman Foundation, a Texas Nonprofit Corporation focused on advancing the development, manufacture, and distribution of medicines and therapies to provide accessible treatments globally announce that it has received exclusive ownership of Trimer Biotech, LLC ("Trimer").
Trimer, a Texas Limited Liability Company, holds exclusive global rights to anti-TNF- monoclonal antibodies, including its lead compound AME-527, which was previously developed by Eli Lilly and Company for autoimmune disorders.
About AME-572
AME-527, Trimer's lead asset, is a fully-humanized, monoclonal antibody engineered for increased affinity for TNF-. An initial study of AME-527 in humans with Rheumatoid Arthritis ("RA") has confirmed tolerability and optimal dose. Patients who responded to AME-527 therapy received treatment for up to a year.
Additional studies for AME-527 for RA and other autoimmune disorders are planned.
About Trimer Biotech, LLC
Trimer is a privately held company headquartered in Plano, TX. Trimer is focused on the development of effective and accessible treatments of autoimmune disorders with novel anti-TNF- monoclonal antibodies.
About Shraman Foundation
Shraman Foundation is a Texas Nonprofit Corporation headquartered in Plano, Texas, USA. Shraman has an area of focus to advance the development, manufacture, and distribution of medicines and therapies to provide accessible treatments globally. For additional information, please contact Amitkumar Patel at apatel@shraman.org.
Media Contact
Shraman Foundation
Source :Shraman Foundation
This article was originally published by IssueWire. Read the original article here.
